Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$18.9M | -$15.0M | -$31.4M | -$39.2M | -$61.4M | -$72.6M | -$152M | -$128M | -$122M |
| Net income | -$33.8M | -$9.30M | -$28.1M | -$36.7M | -$62.0M | -$69.8M | -$143M | -$117M | -$117M |
| EPS (diluted) | -$8.42 | -$4.78 | -$13.15 | -$5.01 | -$2.00 | -$1.70 | -$3.31 | -$21.33 | -$16.95 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.0M | -$18.2M | -$27.9M | -$41.6M | -$51.1M | -$44.8M | -$93.7M | -$92.4M | -$95.2M |
| Capital expenditures | $44.0K | $876K | $1.07M | $990K | $13.0M | $16.8M | $4.46M | $1.12M | $1.74M |
| Free cash flow | -$11.0M | -$19.1M | -$29.0M | -$42.5M | -$64.1M | -$61.5M | -$98.2M | -$93.5M | -$97.0M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $53.3M | $9.47M | $10.6M | $84.3M | $278M | $258M | $160M | $56.5M | $38.9M |
| Total assets | $55.2M | $110M | $81.6M | $154M | $339M | $331M | $207M | $220M | $192M |
| Total liabilities | $5.50M | $5.74M | $27.9M | $44.0M | $35.8M | $38.4M | $37.1M | $33.6M | $33.1M |
| Shareholders' equity | -$26.9M | -$33.5M | -$60.4M | $110M | $303M | $292M | $170M | $187M | $159M |
| Retained earnings | -$33.8M | -$71.4M | -$69.6M | -$106M | -$168M | -$238M | -$381M | -$498M | -$615M |
| Shares (wtd avg diluted) | 5.66M | 2.05M | 2.15M | 7.32M | 31.0M | 41.1M | 43.0M | 5.49M | 6.89M |
Every figure is extracted from Adicet Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.